Question

In: Finance

Opportunity A: a "me-too" oncology drug currently in Phase 3 clinical trials that requires a $100...

  • Opportunity A: a "me-too" oncology drug currently in Phase 3 clinical trials that requires a $100 million investment today (year 0), and if successful, provides annual profits of $100 million over its remaining 10 year patent starting in year 3 (otherwise it returns nothing). Suppose the probability of success is 50%.
  • Opportunity B: a combination therapy of blinatumomab and chemotherapy designed to cure acute lymphoblastic leukemia that requires a $200 million investment today (year 0), and if successful, provides annual profits of $2 billion over its remaining 10 year patent starting in year 11 (otherwise it returns nothing). Suppose the probability of success is 5%.

A) What are the expected annual cash flows of opportunity A for years 3 to 12? (Note: Your answer should be expressed in units of millions of dollars.)

Expected annual cash flow = $___ million

B) What are the expected cash flows of opportunity B for years 11 to 20? (Note: Your answer should be expressed in units of millions of dollars.)

Expected annual cash flow = $____ million

C) Suppose we calculate the NPV of each opportunity by discounting the expected cash flows. Assume a discount rate of 12% per year for opportunity A, and 20% per year for opportunity B. What is the NPV of each opportunity? (Note: Your answer should be expressed in units of millions of dollars.)

NPV opportunity A = $____ million

NPV opportunity B = $____ million

Solutions

Expert Solution

Solution:-

(A)

Expected annual cash flows= Annual cash flows*probability of success

Therefore, using the above formula, we get as below

Expected annual cash flows= $100m*50% = $50 million

(B)

Expected annual cash flows= Annual cash flows*probability of success

Therefor, using the above formula, we get as below

Expected annual cash flows= $2,000m*5% = $100 million

(C)

Discount rates are 12% for A and 20% for B.

NPV (Opportunity A)=Expected annual cash inflow*Sum of PV factors for 10 years (Year 3 to Year 12) - Initial investment*PV Factor (Year 0)

PV factor (Year 0)= 1

Sum of PV factor (Year 3 to Year 12)= 1/(1.12)3 + 1/(1.12)4 + 1/(1.12)5 + 1/(1.12)6...……..+ 1/(1.12)12 = 4.504

NPV (Opportunity A)= $50m*4.504 - $100m*1 = $125.2m

NPV (Opportunity B)=Expected annual cash inflow*Sum of PV factors for 10 years (Year 3 to Year 12) - Initial investment*PV Factor (Year 0)

PV factor (Year 0)= 1

Sum of PV factor (Year 3 to Year 12)= 1/(1.2)3 + 1/(1.2)4 + 1/(1.2)5 + 1/(1.2)6...……..+ 1/(1.2)12 = 2.911

NPV (Opportunity A)= $100m*2.911 - $200m*1 = $91.1m


Related Solutions

As a new targeted anti-cancer drug ‘FCIC-17’ enters Phase III clinical trials, it is determined that...
As a new targeted anti-cancer drug ‘FCIC-17’ enters Phase III clinical trials, it is determined that the drug requires hepatic activation in order to elicit a therapeutic effect. Further studies identify that the sole enzyme involved in the activation of this drug is CYP2C19. Questions: a) Select ONE specific factor (from the categories environmental, genetic or physiological) that may contribute to inter-individual variability in the activation of ‘FCIC-17’, and explain the potential consequences of this variability in terms of treatment...
1) A drug company is studying the effect of a new drug. In clinical trials, the...
1) A drug company is studying the effect of a new drug. In clinical trials, the researcher used a one-tailed test. By using a one-tailed test instead of a two-tailed test, the researcher has A) Expanded the critical region. B) Changed the critical value. C) Decreased the probability of rejecting the H0. 2) In a hypothesis test, when the obtained statistical value is larger than the critical value A) The researcher rejects the null hypothesis. B) The researcher fails to...
Lipitor is a cholesterol-reducing drug. In clinical trials, 94 subjects were treated with the drug and...
Lipitor is a cholesterol-reducing drug. In clinical trials, 94 subjects were treated with the drug and 200 were given a placebo. In the 94 subjects that received the treatment, 8 developed infections while in the placebo group of 200 there were 12 that developed an infection. At α=.05, is there a greater risk of infection from using Lipitor? Assume that P1 is the Percentage of Lipitor users that developed an infection. 1. What is the null hypothesis? 2. What is...
9.Clinical trials of Oxycoting. Oxycoting is a drug used to treat pain, but it is well...
9.Clinical trials of Oxycoting. Oxycoting is a drug used to treat pain, but it is well known for its addictiveness and danger. In a clinical trial, among subjects treated with Oxycotin, 52 developed nausea and 175 did not develop nausea. Among other subjects given placebos, 5 develop nausea and 40 did not develop nausea. Use a 0.05 significance level to test the claim that the proportion of people that develop nausea is greater among the people that take Oxycoting.
ASP Pharmaceuticals has decided to go ahead and start clinical trials on a new drug. The...
ASP Pharmaceuticals has decided to go ahead and start clinical trials on a new drug. The total R&D costs are estimated to reach $750,000,000 with clinical trials mounting to $120,000,000. The current market size is estimated to be 2,000,000 and is expected to grow at 3% every year. The market share ASP hopes to capture in the first year is 8%, and is projected to grow by 20% each year for the next 4 years. A monthly prescription is anticipated...
1) Blood Clot Problem Clinical trials were conducted to test the effectiveness of a drug to...
1) Blood Clot Problem Clinical trials were conducted to test the effectiveness of a drug to prevent blood clots. Among 5674 patients treated with this drug, 147 developed the adverse reaction of nausea. Use a 0.05 significance level to test the claim that 3% of users develop nausea. State the claim, null, and alternative hypothesis. Claim: p                            [ Select ]                       ["<", ">", "≠", "="]...
The process of offshoring (outsourcing an organizational function overseas) is being applied to clinical drug trials...
The process of offshoring (outsourcing an organizational function overseas) is being applied to clinical drug trials with the same speed and enthusiasm as the transplanting by major U.S. corporations of their customer service call centers to countries such as Ireland, India, and increasingly farther east locations. In a report released in June 2010 by Daniel R. Levinson, the inspector general of the Department of Health and Human Services, 80 percent of the drugs approved for sale in 2008 had trials...
A drug is used to help prevent blood clots in certain patients. In clinical trials, among 4244 patients treated with the drug
A drug is used to help prevent blood clots in certain patients. In clinical trials, among 4244 patients treated with the drug, 154 developed the adverse reaction of nausea. Construct a 99% confidence interval for the proportion of adverse reactions.a) Find the best point estimate of the population proportion p.nothing(Round to three decimal places as needed.)b) Identify the value of the margin of error E.E=nothing(Round to three decimal places as needed.)c) Construct the confidence interval.nothing<p<nothing(Round to three decimal places as...
For the clinical trials of a weight-loss drug containing Garcinia Cambogia the subjects were randomly divided...
For the clinical trials of a weight-loss drug containing Garcinia Cambogia the subjects were randomly divided into two groups. The first received an inert pill along with an exercise and diet plan, while the second received the test medicine along with the same exercise and diet plan. The patients do not know which group they are in, nor do the fitness and nutrition advisors. a. Which is the treatment group? b. Which is the control group (if there is one)?...
In clinical trials of the anti-inflammatory drug Inflaminex, adult and adolescent allergy patients were randomly divided...
In clinical trials of the anti-inflammatory drug Inflaminex, adult and adolescent allergy patients were randomly divided into two groups. Some patients received 500mcg of Inflaminex, while some patients received a placebo. Of the 2103 patients who received Inflaminex, 520 reported bloody noses as a side effect. Of the 1671 patients who received the placebo, 368 reported bloody noses as a side effect. Is there significant evidence to conclude that the proportion of Inflaminex users who experienced bloody noses as a...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT